CardioVascular and Interventional Radiology

, Volume 37, Issue 4, pp 1118–1119 | Cite as

Reply to Letter re: General Theory of Predictive Dosimetry for Yttrium-90 Radioembolization to Sites Other Than the Liver

Letter to the Editor

We fully approve the content of this Letter, as it provides a comprehensive roadmap on predictive dosimetry and aims at standardisation and good clinical practice for 90Y-radioembolization to sites other than the liver. The field of application is well defined in the dosimetric assumptions and general points. The formulas are clear and applicable at any site.

As stated in the introduction of this Letter, the safety and efficacy of selective internal radiotherapy (SIRT) is a combination of “technical” and “clinical” success. In this Reply, we would like to highlight some technical aspects that need special attention in order to achieve a therapeutic success.

Before simulation with digital subtraction angiography and 99mTc-macroaggregated albumin (MAA), presimulation imaging should be performed by CT- (or MRI-) angiography to detect vascular variants and abnormalities, to direct additional embolization of vessels, and to plan the most appropriate positioning of the catheter [1]. It is obvious that the position of the catheter and the flow rate should be similar for simulation and treatment. Therefore, it is important to choose a stable position of the catheter, as far as possible from any arterial bifurcation and to store the position of the tip of the catheter (e.g., by means of a screen capture) during simulation to assure a similar distribution of the 99mTc-MAA and 90Y-microspheres.

Posttreatment imaging can assess the distribution of the 90Y-microspheres and should be used to verify and validate the predictive dosimetry, especially in the setting of radioembolization to sites other than the liver. 3D distribution of the 90Y-microspheres can be assessed by 90Y-Bremsstrahlung Emission Computed Tomography (BECT) [2, 3] or 90Y-Time of Flight Positron emission tomography (TOF-PET) [4, 5]. Although the latter technique provides high-resolution images enabling quantification and real posttreatment dosimetry, its application is restricted to a research setting due to the very long acquisition times (at least the double compared to BECT) to obtain sufficient counts.

As tissue mass is an essential component of the equations used for dosimetry, accurate delineation of volumes-of-interest (VOI) is another technical challenge. For organs, the most obvious choice for estimation of the tissue mass is the volumes and radiographic densities derived from CT. However, the use of CT for delineation of viable tumour tissue, especially in small or necrotic target lesions often is less obvious. In this setting, functional imaging might be more appropriate for accurate VOI-delineation. Hybrid imaging by SPECT/CT is indeed a minimal technical requirement for optimal tissue delineation in SIRT-dosimetry, but also requires standardization of the methodology used for VOI-delineation in order to enhance reproducibility and comparability of published data.

Notes

Conflict of interest

Kristoff Muylle and Bruno Vanderlinden have no conflict of interest to declare.

References

  1. 1.
    Vouche M, Vanderlinden B, Delatte P, Lemort M, Hendlisz A et al (2011) New imaging techniques for 90Y microsphere radioembolization. J Nucl Med Radiat Ther 2:113Google Scholar
  2. 2.
    Fabbri C, Sarti G, Cremonesi M, Ferrari M, Di Dia A et al (2009) Quantitative analysis of 90Y Bremsstrahlung SPECT-CT images for application to 3D patient-specific dosimetry. Cancer Biother Radiopharm 24:145–154PubMedCrossRefGoogle Scholar
  3. 3.
    Muylle K, Nguyen J, de Wind A et al (2013) Radioembolization of the spleen: a revisited approach for the treatment of malignant lymphomatous splenomegaly. Cardiovasc Intervent Radiol 36(4):1155–1160PubMedCrossRefGoogle Scholar
  4. 4.
    Lhommel R, Goffette P, Van den Eynde M et al (2009) Yttrium-90 TOF PET scan demonstrates high-resolution biodistribution after liver SIRT. Eur J Nucl Med Mol Imaging 36(10):1696PubMedCrossRefGoogle Scholar
  5. 5.
    Lhommel R, van Elmbt L, Goffette P et al (2010) Feasibility of 90Y TOF PET-based dosimetry in liver metastasis therapy using SIR-spheres. Eur J Nucl Med Mol Imaging 37(9):1654–1662PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2013

Authors and Affiliations

  1. 1.Department of Nuclear Medicine, Jules Bordet InstituteULBBrusselsBelgium
  2. 2.Department of Radiophysics, Jules Bordet InstituteULBBrusselsBelgium
  3. 3.Faculty of Medicine & PharmacyVUBBrusselsBelgium

Personalised recommendations